Baxter Adds Vaccine Production Capacity Via Peptide Therapeutics Deal
Executive Summary
Baxter is enhancing its vaccine production capacity via a $40 mil. equity investment in Peptide Therapeutics.
You may also be interested in...
Baxter
Former Genetic Therapy and Systemix President & CEO Michael Perry, PhD, joins Baxter Oct. 4 as Hyland Immuno VP-global research & development. Baxter's vaccine business has been in a growth phase with the recent purchase of North American Vaccine and an equity investment in Peptide Therapeutics (1"The Pink Sheet" Sept. 25, p. 15)
Baxter
Former Genetic Therapy and Systemix President & CEO Michael Perry, PhD, joins Baxter Oct. 4 as Hyland Immuno VP-global research & development. Baxter's vaccine business has been in a growth phase with the recent purchase of North American Vaccine and an equity investment in Peptide Therapeutics (1"The Pink Sheet" Sept. 25, p. 15)
Powderject Moves Into Marketing Phase Via Medeva Vaccines Acquisition
Powderject's acquisition of Medeva's vaccines business moves the company from the research phase into the marketing of six products, one of which is sold in the U.S.